Finance · SaaS
HONG KONG, August 28, 2026 - On the evening of 27 August, Fosun International announced its 2026 interim results. During the Reporting Period, its total revenue reached RMB86.96 billion; profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%; overseas revenue reached RMB49.16 billion, with its share of total revenue rising to 56.5%; total debt to total capital ratio decreased to 55.7%.
These figures show that Fosun’s results fall in the upper-middle range of the Company’s profit alert (profit attributable to owners of the parent is expected to range from approximately RMB1.5 billion to RMB1.8 billion, representing a year-on-year increase of approximately 127% to 172%) issued on 29 July. This marks Fosun’s return to a growth trajectory following the completion of a systematic realignment of “repairing the roof on a sunny day”.
Over the past few years, Fosun has taken a rather unconventional path. Since 2022, in response to the severe market disruption caused by the pandemic, the Company has advanced its business streamlining and core business-focused strategy, divesting assets and businesses and generating cumulative cash proceeds of approximately RMB75 billion. In March 2026, pursuant to the principle of prudence, Fosun made one-off, non-cash impairment provisions and value revaluations on certain real estate projects with impairment indicators and goodwill and intangible assets of certain non-core business segments. The move drew considerable market attention at the time. At the Company’s 2025 annual results presentation at the end of March, Guo Guangchang, Chairman of Fosun International, explained, “This is about ‘repairing the roof on a sunny day’, allowing Fosun to focus its resources and efforts more effectively on core, high-growth areas.”
The market has now responded to Fosun’s “repairing the roof on a sunny day” initiative. From the announcement of profit alert in early March to 25 August, before its interim results announcement, Fosun’s share price rose sharply from HKD3.6 to HKD5.41, representing an increase of more than 50%. The market has gradually recognized and priced in the Group’s “risk clearance” efforts.
More importantly, the earnings growth driven by the Group’s businesses has begun to materialize. At the 2026 interim results presentation held in Hong Kong on 28 August, Guo Guangchang said: “The strong results recovery we delivered in the first half of the year reflects the outcome of the strategic adjustments we have made over the past few years. Our ‘repairing the roof on a sunny day’ strategy has paid off, allowing us to put historical burdens behind us. These results mark the beginning of Fosun’s continued progress along a trajectory of steady growth.”
Solid Core Businesses, with Pharmaceuticals and Insurance Posting Strong Results
First, let us look at Fosun’s core businesses. In the first half of 2026, its four core businesses — Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade), and the Tourism segment — generated a total revenue of RMB63.88 billion, accounting for 73.5% of the Group’s total revenue, further demonstrating the results of its core business-focused strategy.
Among them, the pharmaceutical and insurance segments delivered particularly strong performance.
In the first half of the year, Fosun Pharma achieved operating revenue of RMB20.377 billion. Revenue from innovative drugs recorded a year-on-year increase of 13.84%, with their contribution to pharmaceutical business revenue rising to 33.35%, establishing innovative drugs as a key growth driver. Its innovative biopharmaceutical platform, Henlius, reported revenue of RMB3.5882 billion, representing a year-on-year increase of 27.3%, while net profit amounted to RMB430.4 million, up 10.3% year-on-year, sustaining growth momentum in revenue and profit. Commercialization of innovative drugs continued to gain traction. During the Reporting Period, Fosun Pharma had a total of 20 indications of 7 innovative drugs approved for launch both domestically and overseas. With their revenue share on a steady rise, innovative drugs have become the main growth engine driving the pharmaceutical business forward.
The insurance segment delivered a stellar performance, with Fosun’s domestic and overseas insurance companies all posting broad-based improvements. Fidelidade’s overall market share in Portugal reached 30.1%, and its international business accounted for 26.7% of its consolidated total business. In the first half of the year, Fidelidade recorded net profit attributable to owners of the parent of EUR165 million, up 23.8% year-on-year, maintaining steady growth.
In Chinese mainland, Pramerica Fosun Life Insurance recorded gross written premiums of RMB8.38 billion in the first half of 2026, up 52.2% year-on-year. Net profit reached RMB780 million, representing a year-on-year increase of 270% and exceeding its net profit for the full year of 2025. Fosun United Health Insurance reported a 36.2% year-on-year increase in revenue and net profit of RMB572 million. Peak Reinsurance’s reinsurance revenue and gross written premiums increased by 25% and 11.8% year-on- year, respectively, while net profit after tax reached USD89.70 million. In April 2026, Moody’s upgraded Peak Re’s rating from Baa1 to A3, with a “stable” outlook.
Guo Guangchang said at the results presentation: “Integrating our insurance business with industries in which we have established competitive advantages has been a strategic priority for Fosun for over three decades — a critical linkage we have long sought to unlock. I believe we have now achieved it. This integration will significantly strengthen our industrial operational capabilities and future profitability, providing sustained momentum for Fosun’s development.”
“Successfully navigating another cycle” is how the market has described Fosun’s latest round of adjustments. A closer look reveals how Fosun has successfully navigated the cycle. On the one hand, the Group has continued to streamline its business to generate cash proceeds. In the first half of the year, the Group generated proceeds equivalent to more than RMB12.0 billion from the divestment of non-strategic and non-core assets. Its total debt to total capital ratio was reduced to 55.7%, while its cash, bank balances and term deposits amounted to RMB61.214 billion. On the other hand, the innovation and globalization strategy that the Group has been pursuing for years has entered a value-realization phase, serving as the core engine driving profit recovery.
Integrated Innovation Strategy Bears Fruit
Since innovative drugs took off in the domestic market in 2025, Fosun has repeatedly broken into the spotlight, with multiple innovative drug business development (BD) drawing significant market attention. In fact, as the saying goes, “One minute on stage takes ten years of hard work off stage”. This series of innovation achievements is the result of Fosun’s forward-looking innovation strategy established nearly two decades ago.
Notably, for more than a decade, Fosun has built a globally integrated innovation system across its core business areas, combining “independent R&D + investment incubation + ecosystem collaboration”, and has consistently made substantial investments in technology innovation. In the first half of this year alone, investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%.
In the first half of this year, Fosun saw a series of innovations come to fruition. HANSIZHUANG, independently developed by Henlius, received approval from the National Medical Products Administration (NMPA) for its perioperative indication in gastric cancer, pioneering a postoperative “chemo-sparing” regimen and making it the world’s first and only anti-PD-1 monoclonal antibody approved for this indication. Its core pipeline asset, HLX43, as a potential best-in-class (BIC) broad-spectrum anti-tumor PD-L1 ADC, has demonstrated preliminary clinical efficacy characterized by high efficacy and low toxicity across multiple solid tumors, including non-small cell lung cancer (NSCLC), with over 1,500 patients enrolled globally. To date, Henlius has 10 products approved in over 60 countries and regions, and has benefited over 1.1 million patients.
In addition, FUMAINING (luvoxmetinib tablets), independently developed by Fosun Pharma, was approved for the treatment of paediatric and adolescent patients with relapsed or refractory Langerhans cell histiocytosis (LCH), continuing to fill the gap in the treatment of rare diseases. In terms of neurodegenerative diseases, Fosun Pharma expanded its global collaboration with AriBio on AR1001, extending its rights to develop and commercialize the product to key markets including the U.S., Europe and Japan. Meanwhile, post-marketing confirmatory clinical trials for sodium oligomannate capsules have progressed steadily, with more than 1,000 patients enrolled as of 31 July 2026. In addition, HT001, an oral NLRP3 inhibitor for the treatment of Parkinson’s disease in-licensed by Hengtai Bio, an investee and incubated company of Fosun Pharma, commenced its Phase I clinical trial in Australia.
Fosun’s innovation achievements demonstrate the forward-looking nature of its innovation strategy and its ability to identify the right opportunities in R&D. As Guo Guangchang remarked at the results presentation, through years of effort, Fosun has built globally integrated innovation capabilities rooted in China. This distinctive strength of Fosun is expected to create greater value for all in the years ahead.
“Fosun has never pursued innovation behind closed doors. Instead, we leverage our resource-integration capabilities and a global perspective to drive smart innovation, bringing together the best technologies, teams and supply chains from around the world to solve real problems. This is how we unlock vast market potential,” said Guo Guangchang.
Unlocking Value through Global Operations
Globalization has been another forward-looking strategic move for Fosun. Since its listing in Hong Kong in 2007, when many Chinese companies were still focused primarily on their domestic markets, Fosun had already begun expanding overseas ahead of its peers.
Nearly two decades later, as a growing number of Chinese companies embrace the view that they must go global or risk being left behind, and seek to capture overseas markets by taking their products overseas, Fosun has already established a profound business presence in more than 40 countries and regions. With local teams operating overseas, it has successfully operated a number of companies within the Fosun ecosystem. “Global operations” have become a defining feature of Fosun’s globalization strategy and a core engine underpinning the development of its businesses.
Guo Guangchang said at the interim results presentation that Fosun continues to strengthen its global operational capabilities. On the one hand, it is helping Chinese products and services enter overseas markets. On the other hand, it is introducing high-quality products and services from around the world into China. Drawing on the global resource-mobilization capabilities it has built over the years, Fosun is able to identify high-quality projects and technologies worldwide and rapidly mobilize the resources needed to advance them.
In the first half of 2026, Fosun’s overseas revenue reached RMB49.16 billion, accounting for 56.5% of total revenue, up 3 percentage points as compared to the same period of 2025 and marking a record high in the proportion of overseas revenue.
In the field of pharmaceuticals and healthcare, Fosun made substantial progress in the global expansion of innovative drugs and commercial business development. Henlius’ HANSIZHUANG was approved for three new indications in the European Union (EU), while HLX11 (pertuzumab injection) was approved in the EU and HLX14 (denosumab injection) was approved in Canada. At the beginning of 2026, Fosun Pharma entered into a strategic partnership with Eisai for HANSIZHUANG, with an aggregate potential consideration exceeding USD300 million, underscoring how the global value of Chinese innovative drugs is being repriced by international markets.
In the first half of the year, Yuyuan generated revenue of RMB532 million in Hong Kong SAR and Macau SAR in the first half of 2026, representing a year-on-year increase of 285.83%, while revenue from the Japanese market reached RMB306 million, representing a year-on-year increase of 6.09%. Laomiao has 15 stores in Hong Kong SAR, Macau SAR, overseas markets and duty-free channels. Club Med has also continued to expand its global footprint, with Club Med Urban Oasis Hangzhou Longwu already open and Club Med South Africa Beach & Safari now in soft opening.
Leveraging Fosun’s global ecosystem, Fidelidade in the insurance segment has expanded its business from Portugal to Portuguese-speaking countries and markets across Europe, Latin America, and Africa. Its international business now accounts for 26.7% of its consolidated total business, with continued growth in Portuguese-speaking countries. Meanwhile, Peak Reinsurance has maintained steady growth thanks to its global business footprint.
The guiding principle behind Fosun’s globalization strategy is “Combining Global Resources with China’s Capabilities”, deeply integrating China’s manufacturing capabilities, service capabilities, and innovation dividends, with global markets. Starting with leveraging China’s growth momentum to establish its business presence, and progressing to a two-way engagement of “mutual empowerment between China and the world”, Fosun has now entered the 3.0 phase of “global organization + local operations”. In this phase, Fosun “truly operates with a global perspective”, having developed the ability to foster cross-regional, cross-cultural, and cross-organizational synergies within its business ecosystem and support the continued growth of its overseas revenue.
At the interim results presentation held on 28 August, Guo Guangchang said: “Fosun’s future development goal is to ‘spur the horse to full speed’. We have already positioned ourselves on a trajectory of steady growth. Going forward, we will continue to advance innovation-driven and global development in industries where we have established competitive advantages, building on our momentum and accelerating further.”
Aug 28 · 08:22·ACN Newswire
Logistics
MUNICH, August 28, 2026--Circus SE (WKN: A2YN35 / ISIN: DE000A2YN355 / XETRA: CA1) today announces the commercial launch of Circus Pods, a standardized ingredient and supply chain infrastructure developed specifically for the company's autonomous sustainment robotic systems, for both defence and commercial use.
Aug 28 · 06:10·Business Wire
Finance · AI
RESULTS HIGHLIGHTS:
- The Revenue for the six months ended 30 June 2026 was approximately HK$2,032.5 million, representing an increase of approximately 10.8% as compared to the same period in 2025. The growth in revenue was primarily attributable to the continued organic growth of the Group—driven by the accelerating adoption of digitalization across the global dental industry, particularly in Europe and Australia—alongside the stabilization and operational turnaround of the Mainland China market. This expansion was partially offset by a revenue decline in North America, which was impacted by a softer macroeconomic environment affecting high-value discretionary procedures, as well as management’s strategic decision to rationalize loss-making Dental Service Organization (DSO) accounts to optimize customer mix and protect margins.
- The Gross Profit Margin for the six months ended 30 June 2026 was approximately 58.1%; the gross profit was approximately HK$1,180.9 million, reflecting an increase of approximately 17.4% as compared to the same period in 2025.
- The Group’s EBITDA for the six months ended 30 June 2026 was approximately HK$ 560.7 million, representing an increase of approximately 22.8% as compared to the same period in 2025.
- The Group’s Net Profit for the six months ended 30 June 2026 was approximately HK$ 377.6 million, representing an increase of 30.8% as compared to the same period in 2025.
- Basic earnings per share for the six months ended 30 June 2026 amounted to HK40.07 cents, representing an increase of approximately 31.9% as compared to the same period in 2025.
- The Board declared an interim dividend of HK14.0 cents per ordinary share for the six months ended 30 June 2026.
ADDITIONAL HIGHLIGHTS:
- For the six months ended 30 June 2026, the Group’s digital solution cases that are produced from its Mainland China, Thailand and Vietnam production facilities increased to approximately 627,773 cases, reflecting an increase of 29.2% as compared with the same period in 2025 as a result of our clients’ continued adoption of intra-oral scanners.
HONG KONG, August 28, 2026 - 27 August 2026, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, is pleased to announce the unaudited interim results for the six months ended 30 June, 2026 (“the Period”).
In the first half of 2026, the global macroeconomic environment remains uncertain, with geopolitical tensions and potential tariff changes continuing to create headwinds. However, the Group’s geographically diversified production footprint and global distribution network position us strongly to navigate these challenges. Unlike many competitors reliant on single-country manufacturing, our operations across China, Vietnam and Thailand (including the newly acquired Hexa Ceram) provide superior resilience and flexibility. This strategy, combined with our ability to adapt quickly to local market conditions, enables the Group to mitigate risks and capitalise on opportunities across regions.
The dental industry has continued to demonstrate remarkable resilience, underpinned by irreversible demographic trends, including aging populations and increasing awareness of oral health, which drive consistent long-term demand. Building on our well performance, the Group is well placed to sustain momentum and further strengthen its market leadership.
Digitalisation remains an irreversible industry trend that is accelerating consolidation of the dental prosthetics industry. We are at the forefront of this transformation, with digital solution cases now representing approximately 35–43% of total volume. Our centralized digital workflows, intra-oral scanner partnerships, proprietary solutions and global education centers have enhanced operational efficiency, reduced turnaround times and delivers superior customer experiences. These initiatives create high entry barriers and will continue to drive margin expansion and market share gains in the coming years.
European Businesses
During the period under review, the European market recorded a revenue of approximately HK$1,093.3 million, representing an increase of approximately HK$173.0 million as compared with the six months ended 30 June 2025. This geographic market accounted for approximately 53.8% of the Group’s total revenue. The increase of revenue from the European market was attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.
North American Businesses
During the period under review, the North American market recorded a revenue of approximately HK$331.3 million, representing a decrease of approximately HK$34.4 million as compared with the six months ended 30 June 2025. This geographic market accounted for approximately 16.3% of the Group’s total revenue.
The top-line contraction in North America was primarily driven by a softer macroeconomic environment, which temporarily weighed on consumer sentiment and demand for high-value discretionary cosmetic procedures. In response, management proactively initiated a strategic rationalization of loss-making Dental Service Organization (DSO) accounts aimed at optimizing the customer mix, protecting gross margins, and focusing resources on higher-margin accounts.
Concurrently, the Group’s diversified production footprint across the US, China, Vietnam, and Thailand continues to afford significant supply chain agility to navigate trade and tariff complexities—a key differentiator in the market. Demonstrating the resilience of this strategy, our US import business unit delivered a 1.4% period-on-period sales growth in the first half of 2026. This performance underscores how the accelerating trend toward clinical digitalization and the cost-competitiveness of our imported product lines have effectively mitigated and offset the impact of US tariffs.
Greater China Businesses
During the period under review, the Greater China market recorded a revenue of approximately HK$300.0 million, representing an increase of approximately HK$6.8 million as compared with six months ended 30 June 2025. This geographic market accounted for approximately 14.8% of the Group’s total revenue.
Regional performance reflected diverging market dynamics across territories. In local currency terms, sales in Mainland China increased by approximately 0.9% year-on-year, signalling that the market has largely bottomed out from the initial impact of Volume-Based Procurement (VBP) policies and prolonged price competition. To protect sustainable profitability, the Group deliberately pivoted away from low-margin segments to focus on serving mid- to high-value customers. Conversely, sales in the Hong Kong market decreased by approximately 8.5% in local currency year-on-year. This contraction was primarily driven by a temporary reduction in local patient visits, as cross-border dental consumption increased due to aggressive promotions for dental treatments offered by Mainland China clinics targeting Hong Kong residents.
Despite these near-term shifts, the Group remains optimistic about the mid- to long-term outlook for the Greater China region. Government procurement measures in Mainland China are expected to standardize prosthetic pricing and enhance market transparency, creating a more level playing field where the Group’s leading brand reputation, production scale, and operational efficiency serve as distinct competitive advantages. To capture evolving market demand, the Group is actively expanding its product portfolio, particularly in mid-end offerings and products.
Australian Businesses
During the period under review, the Australian market recorded a revenue of approximately HK$162.8 million, representing an increase of approximately HK$24.9 million as compared with the six months ended 30 June 2025. This geographic market accounted for approximately 8.0% of the Group’s total revenue. The increase in revenue from Australia was primarily driven by strong adoption of digital dental products and anti-snoring devices, and wins in dental service organization (DSO) customers.
Other Markets
Other markets primarily include Indian Ocean countries, Malaysia, Taiwan, Singapore and Thailand. For the six months ended 30 June 2026, these markets recorded a revenue of approximately HK$145.2 million, representing an increase of approximately HK$27.4 million as compared with the six months ended 30 June 2025. This geographic market accounted for approximately 7.1% of the Group’s total revenue. The increase in revenue from Other markets was primarily driven by the strong revenue contributions from Thailand, Singapore and Malaysia. The scaled manufacturing hubs in Thailand and Vietnam have enhanced regional supply efficiency, broadened product availability, and strengthened the Group’s competitive footprint in the region.
Future Prospects and Strategies
Looking ahead, the Group remains committed to reinforcing its worldwide leading position through a multi-dimensional approach. We will continue to pursue selective acquisitions, joint ventures and partnerships to expand and complement our product offerings, particularly in our high-growth clear aligner, Trioclear, while strengthening our distribution and sales networks. Ongoing investments in mass-scale production facilities, AI, automation, research and development, and digital innovation will drive efficiency gains and secure our position at the forefront of the industry.
With the Board’s extensive experience and prudent governance, the Group is well positioned to seize new business opportunities while remaining strict financial discipline to safeguard Shareholders’ interests. The Board expresses its sincere gratitude to our dedicated employees, loyal customers, suppliers, and business partners for their unwavering commitment. Their collective efforts have been instrumental in delivering another year of record results and will continue to support the Group’s long-term success.
About Modern Dental Group
Modern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices.
Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 30 countries and serve over 35,000 customers.
Aug 28 · 01:30·ACN Newswire
SaaS · Logistics
Oracle has been named a Leader in the 2026 Gartner® Magic Quadrant™ for Supply Chain Management Suites for Oracle Fusion Cloud Supply Chain &...
Aug 27 · 15:18·Oracle
Logistics
MINNEAPOLIS, August 27, 2026--Priority Courier Experts, a leading provider of same-day logistics services, has acquired INPAX Shipping Solutions
Aug 27 · 14:30·Business Wire
Logistics
Colorado Springs, Colorado--(August 27, 2026) - Compassion International artists CeCe Winans, for KING + COUNTRY, and Warehouse Worship, among others, will take the stage at Big Church Festival and venues across the UK this summer, using their platforms to inspire fans to support children living in poverty through Compassion's child sponsorship program.Welcoming approximately 35,000 attendees annually, Big Church Festival brings together music lovers, families, churches and...
Aug 27 · 13:00·Newsfile
Logistics
Exclusive program uses proprietary navigation data, reflecting routing choices made before the truck moves, to deliver underwriting precision and safer outcomes for small fleets. SAN FRANCISCO and PHOENIX, Aug. 27, 2026 -- Corgi Insurance and Trucker Path Insurance today...
Aug 27 · 12:03·PR Newswire
Logistics
BranchOut Secures Approximately $750,000 in Initial Orders for New Front-of-Club Multipack Product Line and Dried Cheesecake Bites
Aug 27 · 12:01·GlobeNewswire
Energy · Logistics
Nearly $70 billion of clean energy projects are expected to generate 14,000 megawatts, support 23,000 jobs and contribute $31 billion to Canadian GDPCanada is advancing mine-enabling transmission and pre-development work through the First and Last Mile FundUp to $8 billion is planned for 5 Wing Goose Bay within a broader $32 billion northern basing programSAGA's Labrador portfolio is directly aligned with growing North American demand for secure supplies of titanium, vanadium, iron, uranium and...
Aug 27 · 11:30·Newsfile
Finance · AI
XIAMEN, August 27, 2026 - August 26, 2026, Reconova Technologies Co., Ltd. ("Reconova" or the "Company", Stock code: 7656.HK) today released its first interim results since its listing. During the reporting period, the Company achieved revenue of approximately RMB102 million, representing a year-on-year increase of 58.7%. The revenue growth was primarily driven by the synergistic momentum across its three business segments, underpinned by a solid core business foundation. R&D expenses accounted for approximately 48.8% of revenue, as strategic investments continued to build robust technological moats for the Company.
Operating Performance Steadily Improves, Operational Efficiency Continuously Optimised
From a profitability perspective, the Company recorded a net loss of approximately RMB64 million during the reporting period, narrowing by 6.7% year-on-year. This improvement was achieved despite a continued increase in R&D investment, which rose 51.2% year-on-year. As the Company is in the strategic investment phase for embodied intelligence, R&D expenses account for nearly half of revenue. The net loss was primarily attributable to increased R&D investment in embodied intelligence and one-off listing-related expenses incurred during the period.
In terms of operational efficiency, selling and distribution expenses declined by approximately 5.3% year-on-year alongside revenue expansion, reflecting continuous efficiency gains. While the net loss narrowed year-on-year, trade receivables decreased to approximately RMB510 million, down 13.0% from the end of the previous year, indicating a notable improvement in collection efficiency.
Looking at forward revenue visibility, contract liabilities stood at approximately RMB12 million as at the end of the reporting period, up 420% from the beginning of the year. Contract liabilities represent advance payments from customers for goods or services not yet delivered; these amounts will be progressively recognised as revenue in subsequent accounting periods, providing greater visibility into future revenue.. For technology companies in a strategic investment phase, trends in contract liabilities often better reflect the true trajectory of the business than current-period net profit.
Three Business Segments Achieve Synergistic Growth, Customer Ecosystem Continuously Strengthened
During the reporting period, all three business segments achieved year-on-year growth with ongoing structural optimisation, demonstrating the core business's sustainable cash-generating capability.
The Intelligent Civil Aviation segment generated revenue of approximately RMB3 million, up 319.1% year-on-year, benefiting from enhanced customer stability. The Company maintained its No. 1 market position in China's enterprise vision intelligence product market for civil aviation, with its products deployed in over 60% of China's airports with annual passenger throughput exceeding 10 million. Benchmark projects continue to be replicated and iterated. It is worth noting that the civil aviation sector exhibits pronounced seasonal characteristics: due to the annual budget execution cycle of airports and project acceptance timelines, revenue recognition for this segment is typically concentrated in the second half of the year, particularly in the fourth quarter.
The Smart Commercial segment accelerated the acquisition and servicing of high-value customers, driving growth in average customer value and transaction volume. Revenue reached approximately RMB34 million, up 95.5% year-on-year. The SINHON Business System for commercial spaces is being deployed at an accelerating pace, achieving rapid growth and a more diversified revenue base.
The Smart Driving Safety segment generated revenue of approximately RMB66 million, up 41.2% year-on-year. A significant increase in new customer order volumes drove sales expansion.
Full-Stack Technology System Evolves, Embodied Intelligence Achieves Multiple Commercialisation Milestones
With 14 years of expertise in vision intelligence, Reconova has built an integrated enterprise-grade embodied intelligence core technology framework spanning "perception–cognition–physical execution," and is steadily advancing the large-scale deployment of commercial robot products for productivity-focused scenarios.
In terms of concrete progress, the "AntOne" airport baggage handling robot, launched in September 2025, has completed pilot deployment at a major Chinese airport with more than 10 million annual passengers, supporting 24/7 uninterrupted operation. In April 2026, the Company iteratively launched its new VTFLA embodied intelligence technology architecture. Building on the conventional VLA (Vision-Language-Action) framework, VTFLA integrates multi-modal input perception including vision, tactile and force feedback. Its core design philosophy is to process over 80% of intelligence at the edge, employing a dual-system fast-slow coordination architecture that decouples and coordinates task planning with real-time control. The Company plans to further advance R&D in edge-side lightweight embodied intelligence technology, continuously enhancing multi-modal perception and execution capabilities.
At the recently concluded 2026 World Robot Conference (WRC), the Company comprehensively presented an embodied intelligence solution for airport productivity scenarios. Through human-machine systems and multi-robot collaborative operations, the solution reshapes traditional manual baggage handling operations, creating a safe, reliable, and flexibly adaptable full-chain intelligent baggage handling system. In addition, the Company has initiated R&D on a wheeled dual-arm robot, expected to be launched in 2027 and commercialised in 2028. Its application scenarios will expand from fixed-position baggage handling to mobile loading and unloading operations under aircraft, and gradually extend to warehousing, industrial automation, and other scenarios. During the conference, the Company also signed a strategic cooperation agreement with SIIC Tech Capital to jointly build the Hong Kong Embodied Intelligence Super Accelerator, advancing industrial commercialisation and international expansion.
Globalisation Strategy Fully Launched, Overseas Markets Achieve Multi-Point Breakthroughs
For international expansion, the Company adopts a strategy of "expanding from nearby markets to more distant regions," with an initial focus on Southeast Asia and the Middle East. Currently, the Company has launched Proof of Concept (PoC) pilot projects at Hamad International Airport in Doha, Qatar, and Tashkent International Airport in Uzbekistan. The rollout follows the principle of "prioritising flagship airports first, then radiating to long-tail customers": the first phase focuses on hub airports in the Middle East and Southeast Asia to establish benchmark cases, before progressively expanding to long-tail customers and subsequently entering European and American markets. The Company is replicating its vision AI and embodied intelligence experience accumulated at domestic airports to global markets that are undergoing large-scale smart airport construction.
In terms of partnership models, the Company emphasises local ecosystem collaboration and the export of technology standards, combined with product localisation, adopting an asset-light, deep-collaboration approach. Approximately 10.4% of the IPO net proceeds have been earmarked for expanding overseas sales channels, providing financial support for the globalisation strategy.
Strategy Focused on Productivity Scenarios, Long-Term Market Potential Gradually Unlocks
The Company adheres to a highly focused and disciplined strategic principle, concentrating on "productivity tools" in handling, depalletizing/palletizing, and specialty scenarios, rather than pursuing broad concepts such as consumer-grade robots or general-purpose humanoid robots. In the short term, the three business segments — Intelligent Civil Aviation, Smart Commercial, and Smart Driving Safety — will continue to generate stable cash flow. Over the medium to long term, leveraging a universal vision intelligence foundation reusable across scenarios, the Company will continuously strengthen its full-stack embodied intelligence core technology framework, iterate multiple categories of commercial robots, and complete a strategic upgrade from vision intelligence solutions to an integrated "perception–cognition–physical execution" enterprise-grade embodied intelligence framework.
Embodied intelligence has been included as a key future industry to be cultivated under China's 15th Five-Year Plan. According to Frost & Sullivan forecasts, China's enterprise vision intelligence market will exceed RMB162.7 billion by 2030. As B2B customers' demand for cost reduction and efficiency improvement continues to rise and the technology maturity curve crosses its inflection point, commercial robots are expected to enter a period of accelerated demand growth in productivity scenarios such as airport baggage handling, warehousing logistics, and industrial automation over the next three to five years.
Leveraging its 14-year vision intelligence foundation and multi-scenario engineering delivery experience, Reconova is accelerating the deployment of embodied intelligence in real industrial scenarios, completing its transition from vision intelligence to enterprise-grade embodied intelligence, with long-term market potential gradually unlocking.
About Reconova Technologies Co., Ltd.
Reconova Technologies Co., Ltd. (Stock code: 7656.HK) is a leading enterprise vision intelligence company in China, listed on the Main Board of The Stock Exchange of Hong Kong Limited on 8 July 2026. The Company provides a series of visual perception, visual cognition, and visual reasoning intelligence products applied across civil aviation, commercial spaces, and driving safety scenarios. Ranked first in China's enterprise vision intelligence product market for civil aviation by 2025 revenue, Reconova is advancing its strategic evolution from vision intelligence to enterprise-grade embodied intelligence.
Aug 27 · 11:18·ACN Newswire
Logistics
Toronto, Ontario--(August 26, 2026) - Cybeats Technologies Corp. (CSE: CYBT) (OTCQB: CYBCF) ("Cybeats" or the "Company"), a leading provider of software supply-chain security and SBOM management solutions, announces that it will release its financial results for the three and six months ended June 30, 2026 ("Q2 2026") after market close on Monday August 31, 2026. Cybeats CEO Justin Leger will host a live webinar that same day at 4:30 PM ET to review the Company's financial...
Aug 26 · 20:42·Newsfile
Finance · Logistics
Maroussi, Greece, August 26, 2026 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), an international diversified shipping company with a focus on the seaborne transportation of refined petroleum products and dry bulk commodities, today announced the following:
Aug 26 · 20:15·GlobeNewswire